[Ip-health] CDIP 17: Asia Pacific and African Group raise concerns re: WIPO's position on the UN High-Level Panel on Access to Medicines
thiru at keionline.org
Wed Apr 20 04:16:02 PDT 2016
CDIP 17: Asia Pacific and African Group raise concerns re: WIPO's position
on the UN High-Level Panel on Access to Medicines
Submitted by thiru on 11. April 2016 - 4:04
The World Intellectual Property Organization (WIPO) is convening its 17th
session of the Committee on Intellectual Property and Development (CDIP17)
from 11 April 2016 to 15 April 2016. The mandate of the Committee is to
"develop a work-program for implementing the 45 adopted Development Agenda
recommendations" and "monitor, assess, discuss and report on the
implementation of all recommendations adopted" (Source: WIPO page on the
Committee on Development And Intellectual Property
The morning session, devoted to opening statements, witnessed three
references to the United Nations High-Level Panel on Access to Medicines
made by India, Pakistan and Indonesia.
India, on behalf of the Asia Pacific Group (a group which includes Iran,
India, Pakistan, Indonesia, Singapore, Republic of Korea, Philippines,
We appreciate WIPO’s engagement with other UN bodies. The group would like
to know the terms of reference of this engagement especially with World
Trade Organisation and World Health Organisation on areas particularly
where there is no consensus among member states. In this regard, we would
also request detailed information about WIPO’s engagement with the UN
Secretary General’s High Level Panel on Access to Medicines and the mission
briefings in Geneva and New York on this subject.
Pakistan expressed the following concerns:
We have repeatedly requested the secretariat to brief us about the terms of
reference under which the organization engages with other UN bodies
especially on areas in which there is no consensus among member states.
We received a demarche from NGOs about the secretariat mission briefings
related to the UNSG High-Level Panel process in Geneva and New York where
the secretariat expressed WIPO’s sensitivity by questioning, and I quote,
“the prima facie assumption in the mandate of the HLP that there is policy
incoherence between IP laws and regulations to encourage innovation and the
imperative of delivering medicines and other health services to those in
This runs counter to the DA itself, which recognizes the existence of
policy incoherence between IP protection and the public interest and seeks
to encourage WIPO and its member States to address such policy incoherence.
We would request the secretariat to explain the situation and brief member
states about WIPO’s input to the HLP.
In the afternoon, following the presentation of the Director General’s
Report on Implementation of the Development Agenda, Nigeria, on behalf of
the African Group made the following intervention:
6. Based on the contents of the report, the Africa Group would like to make
the following requests:
More information from WIPO on its involvement in the UN High Level Panel on
Access to Medicines; including making available the substantive input
submitted to the High Level panel.
South Africa followed on:
- However, we also noted that the DG’s report did not make mention of
WIPO’s participation in the Expert ADVISORY GROUP to the United Nation
Secretary General’s High Level Panel on Access to Medicine whose mandate is
to review and assess proposals and recommend solutions for remedying the
policy coherence between the IP, human rights, trade rules and public
- Taking into account the sensitivity expressed by WIPO on the prima
facie assumption of the mandate that there is policy incoherence, it would
important and helpful that clarity be provided on WIPO”s official
position on the mandate of the High Level Panel and its involvement in the
As the DG is aware, the interface between IP and public health is
dominating current debate across the world and having heard the briefings
made to the
Panel in Johannesburg, it is indeed a cause for concern.
- In order for transparency, it is imperative that WIPO informs Member
States on its participation and contribution to the High Level Panel. The
Health Organisation and the United Nations Office of the High
Commissioner of Human Rights have already uploaded their contribution. Can
General kindly inform when the WIPO’s contribution would be available on
In his response, the Director-General (Francis Gurry) stated:
These are delicate situations for the Secretariat. We are only there as a
Secretariat. Nigeria rightfully pointed out, there are divergences among
the member states. There's no policy instrument...We regard our role as an
information role. The SDGs are a live process, as is the process relating
to the SDGs. We would be happy to upload our submission to the UN HLP.
I would not refer it as "policy incoherence"; I would refer it to as
"tension". In my personal view, it's a tension that will continue to exist.
We need to be more innovative than the microbes, there's not much use for
innovation if we can't use it.
Following the response of the Director-General, Brazil stepped into the
Regarding the contribution of WIPO to the United Nations’ system, I'd like
also to mention the UN Secretary-General’s High-Level Panel on Access to
Medicines. We thank the clarification provided by the Director-General.
Nevetheless, the statements made by WIPO representatives during briefing
meetings last February caused concern by apparently questioning the panel’s
mandate. The complex interplay between the protection of intellectual
property and the imperative of ensuring access for life-saving medicines is
not a new issue. It was object of a unanimous WTO Decision in 2001 that
generated many initiatives such as the Paragraph 6 system. Additionally,
the anti-competitive use of intellectual property rights in a way that
threatens access to medicines and reduces the general welfare of society is
well-documented in the European Commission’s Pharmaceutical Sector Inquiry.
The High-Level Panel was established precisely to discuss ways of providing
incentives for both innovation and access. These incentives can take many
forms, such as the Medicines Patent Pool or the Drugs for Neglected
Diseases Initiatives, among others. The trilateral study by WIPO, WTO and
WHO touched upon some of these issues. Considering its experience in the
subject, WIPO can and should bring a positive contribution to the
discussions of the High-Level Panel. We look forward to read WIPO's
contribution to the Panel, when available.
The representative of the Third World Network (TWN) expounded on the
importance of the UN HLP's work in remedying the policy incoherence between
human rights obligations and trade rules.
With regard to the UN Secretary General High Level Panel on Access to
Medicines, we note the response of the DG, which mentioned that it is not a
matter of policy incoherence but a tension between intellectual property
and public health.
International human rights law obligates countries to respect, to protect
and to fulfill socio, economic and cultural rights such as the right to
health and right to science. Access to affordable generic alternatives is a
prerequisite to fulfillment of the right to health. The right to science
obligates states to ensure its citizens enjoy the benefits of scientific
progress and its applications. However, this is not possible without
affordable access. The international IP regime, especially product patent
protection and data exclusivity, incapacitates developing countries from
fulfilling their human rights obligations, thus resulting in policy
incoherence between the international obligations on human rights and trade
law and in this context IP law. Twenty years of experience with TRIPS shows
that the strategy of using TRIPS flexibilities to address the incoherence
between human rights and trade law has not delivered the desired result,
for a variety of reasons. Similarly, the existing IP regime creates policy
incoherence with sustainable development goals (SDG) especially with
targets sets in SDG 3 on communicable and non- communicable diseases, which
cannot be met without access to new affordable medical products.
The concern is that of policy incoherence. These issues cannot simply be
dismissed as being a mere tension.
More information about the Ip-health